# AI-based Social Software to Manage wARfarin Therapy

> **NCT03870581** · NA · UNKNOWN · sponsor: **Wuhan Asia Heart Hospital** · enrollment: 500 (estimated)

## Conditions studied

- Anticoagulant-induced Bleeding
- Warfarin Sodium Causing Adverse Effects in Therapeutic Use

## Interventions

- **BEHAVIORAL:** AI-based social software management model
- **BEHAVIORAL:** Human-based social software management model

## Key facts

- **NCT ID:** NCT03870581
- **Lead sponsor:** Wuhan Asia Heart Hospital
- **Sponsor class:** OTHER
- **Phase:** NA
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2019-05-01
- **Primary completion:** 2021-04-30
- **Final completion:** 2021-05-01
- **Target enrollment:** 500 (ESTIMATED)
- **Last updated:** 2019-03-12


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03870581

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03870581, "AI-based Social Software to Manage wARfarin Therapy". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT03870581. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*